Body Composition and Ectopic Lipid Changes With Biochemical Control of Acromegaly
- PMID: 28945897
- PMCID: PMC6283448
- DOI: 10.1210/jc.2017-01210
Body Composition and Ectopic Lipid Changes With Biochemical Control of Acromegaly
Abstract
Context: Acromegaly is characterized by growth hormone (GH) and insulinlike growth factor-1 (IGF-1) hypersecretion, and GH and IGF-1 play important roles in regulating body composition and glucose homeostasis.
Objective: The purpose of our study was to investigate body composition including ectopic lipids, measures of glucose homeostasis, and gonadal steroids in patients with active acromegaly compared with age-, body mass index (BMI)-, and sex-matched controls and to determine changes in these parameters after biochemical control of acromegaly.
Design: Cross-sectional study of 20 patients with active acromegaly and 20 healthy matched controls. Prospective study of 16 patients before and after biochemical control of acromegaly.
Main outcome measures: Body composition including ectopic lipids by magnetic resonance imaging/proton magnetic resonance spectroscopy; measures of glucose homeostasis by an oral glucose tolerance test; gonadal steroids.
Results: Patients with active acromegaly had lower mean intrahepatic lipid (IHL) and higher mean fasting insulin and insulin area under the curve (AUC) values than controls. Men with acromegaly had lower mean total testosterone, sex hormone-binding globulin, and estradiol values than male controls. After therapy, homeostasis model assessment of insulin resistance, fasting insulin level, and insulin AUC decreased despite an increase in IHL and abdominal and thigh adipose tissues and a decrease in muscle mass.
Conclusions: Patients with acromegaly were characterized by insulin resistance and hyperinsulinemia but lower IHL compared with age-, BMI-, and sex-matched healthy controls. Biochemical control of acromegaly improved insulin resistance but led to a less favorable anthropometric phenotype with increased IHL and abdominal adiposity and decreased muscle mass.
Copyright © 2017 Endocrine Society
Figures


Similar articles
-
[Lowered ghrelin levels in acromegaly—normalization after treatment].Endokrynol Pol. 2005 Nov-Dec;56(6):862-70. Endokrynol Pol. 2005. PMID: 16821203 Clinical Trial. Polish.
-
Increased GH/IGF-I Axis Activity Relates to Lower Hepatic Lipids and Phosphor Metabolism.J Clin Endocrinol Metab. 2023 Sep 18;108(10):e989-e997. doi: 10.1210/clinem/dgad206. J Clin Endocrinol Metab. 2023. PMID: 37104943 Free PMC article.
-
Adipose Tissue Redistribution and Ectopic Lipid Deposition in Active Acromegaly and Effects of Surgical Treatment.J Clin Endocrinol Metab. 2015 Aug;100(8):2946-55. doi: 10.1210/jc.2015-1917. Epub 2015 Jun 2. J Clin Endocrinol Metab. 2015. PMID: 26037515 Free PMC article. Clinical Trial.
-
Place of cabergoline in acromegaly: a meta-analysis.J Clin Endocrinol Metab. 2011 May;96(5):1327-35. doi: 10.1210/jc.2010-2443. Epub 2011 Feb 16. J Clin Endocrinol Metab. 2011. PMID: 21325455 Review.
-
Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs.Neuroendocrinology. 2006;83(3-4):249-57. doi: 10.1159/000095535. Epub 2006 Oct 13. Neuroendocrinology. 2006. PMID: 17047390 Review.
Cited by
-
Changes in Cross-Sectional Area of the Median Nerve and Body Composition Parameters after Treatment of Acromegaly: 1 year Follow-Up.Int J Endocrinol. 2022 Oct 13;2022:8766046. doi: 10.1155/2022/8766046. eCollection 2022. Int J Endocrinol. 2022. PMID: 36277124 Free PMC article.
-
Increased ATP synthesis might counteract hepatic lipid accumulation in acromegaly.JCI Insight. 2020 Mar 12;5(5):e134638. doi: 10.1172/jci.insight.134638. JCI Insight. 2020. PMID: 32106111 Free PMC article.
-
Body Composition Changes with Long-term Pegvisomant Therapy of Acromegaly.J Endocr Soc. 2021 Feb 1;5(3):bvab004. doi: 10.1210/jendso/bvab004. eCollection 2021 Mar 1. J Endocr Soc. 2021. PMID: 33553983 Free PMC article.
-
Non-Invasive Assessment of Metabolic Dysfunction-Associated Steatotic Liver Disease and Cardiovascular Risk in Acromegaly Indicates Persistence of Cardiac Risks Despite Biochemical Disease Control.J Clin Med. 2025 Jul 8;14(14):4822. doi: 10.3390/jcm14144822. J Clin Med. 2025. PMID: 40725515 Free PMC article.
-
Body Composition, Sarcopenia, and Serum Myokines in Acromegaly: A Narrative Review.J Bone Metab. 2024 Aug;31(3):182-195. doi: 10.11005/jbm.2024.31.3.182. Epub 2024 Aug 31. J Bone Metab. 2024. PMID: 39307519 Free PMC article.
References
-
- Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev. 2004;25(1):102–152. - PubMed
-
- Møller N, Jørgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev. 2009;30(2):152–177. - PubMed
-
- Bengtsson BA, Brummer RJ, Bosaeus I. Growth hormone and body composition. Horm Res. 1990;33(Suppl 4):19–24. - PubMed
-
- Freda PU, Shen W, Heymsfield SB, Reyes-Vidal CM, Geer EB, Bruce JN, Gallagher D. Lower visceral and subcutaneous but higher intermuscular adipose tissue depots in patients with growth hormone and insulin-like growth factor I excess due to acromegaly. J Clin Endocrinol Metab. 2008;93(6):2334–2343. - PMC - PubMed
-
- Sesmilo G, Fairfield WP, Katznelson L, Pulaski K, Freda PU, Bonert V, Dimaraki E, Stavrou S, Vance ML, Hayden D, Klibanski A. Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant. J Clin Endocrinol Metab. 2002;87(4):1692–1699. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous